Aldose reductase inhibition

Emerging drug target for the treatment of cardiovascular complications

Aramati B M Reddy, Kota Ramana

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Diabetes is a major metabolic disorder and leading cause of morbidity and mortality in the developed world. Indeed, vascular complications are the major cause of mortality in diabetics. Impaired glucose metabolism has been implicated as a cause for the observed cardiac dysfunction in diabetics. Dramatic increase in polyol pathway flux during hyperglycemia could cause damage to blood vessels that leads to heart failure. Recent investigations and patent applications suggest the interesting and important role of polyol pathway enzyme, aldose reductase (AR) in mediating oxidative stress-induced inflammatory signals. AR inhibitors have been shown to prevent or delay the onset of cardiovascular complications such as ischemic injury, restenosis and atherosclerosis. In this review, we have focused on describing the pivotal role of AR in the pathogenesis of cardiovascular complications and use of AR inhibitors as emerging therapeutic strategies in preventing cardiovascular complications.

Original languageEnglish (US)
Pages (from-to)25-32
Number of pages8
JournalRecent Patents on Cardiovascular Drug Discovery
Volume5
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Aldehyde Reductase
Pharmaceutical Preparations
Blood Vessels
Mortality
Hyperglycemia
Atherosclerosis
Oxidative Stress
Heart Failure
Morbidity
Glucose
Wounds and Injuries
Enzymes
polyol
Therapeutics

Keywords

  • Aldose reductase
  • Cardiovascular & Ischemia
  • Diabetes
  • Inflammation
  • Oxidative stress
  • Polyol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Drug Discovery

Cite this

Aldose reductase inhibition : Emerging drug target for the treatment of cardiovascular complications. / Reddy, Aramati B M; Ramana, Kota.

In: Recent Patents on Cardiovascular Drug Discovery, Vol. 5, No. 1, 01.2010, p. 25-32.

Research output: Contribution to journalArticle

@article{d2b41465f40a46c0905d163abc1da646,
title = "Aldose reductase inhibition: Emerging drug target for the treatment of cardiovascular complications",
abstract = "Diabetes is a major metabolic disorder and leading cause of morbidity and mortality in the developed world. Indeed, vascular complications are the major cause of mortality in diabetics. Impaired glucose metabolism has been implicated as a cause for the observed cardiac dysfunction in diabetics. Dramatic increase in polyol pathway flux during hyperglycemia could cause damage to blood vessels that leads to heart failure. Recent investigations and patent applications suggest the interesting and important role of polyol pathway enzyme, aldose reductase (AR) in mediating oxidative stress-induced inflammatory signals. AR inhibitors have been shown to prevent or delay the onset of cardiovascular complications such as ischemic injury, restenosis and atherosclerosis. In this review, we have focused on describing the pivotal role of AR in the pathogenesis of cardiovascular complications and use of AR inhibitors as emerging therapeutic strategies in preventing cardiovascular complications.",
keywords = "Aldose reductase, Cardiovascular & Ischemia, Diabetes, Inflammation, Oxidative stress, Polyol",
author = "Reddy, {Aramati B M} and Kota Ramana",
year = "2010",
month = "1",
doi = "10.2174/157489010790192683",
language = "English (US)",
volume = "5",
pages = "25--32",
journal = "Recent Patents on Cardiovascular Drug Discovery",
issn = "1574-8901",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Aldose reductase inhibition

T2 - Emerging drug target for the treatment of cardiovascular complications

AU - Reddy, Aramati B M

AU - Ramana, Kota

PY - 2010/1

Y1 - 2010/1

N2 - Diabetes is a major metabolic disorder and leading cause of morbidity and mortality in the developed world. Indeed, vascular complications are the major cause of mortality in diabetics. Impaired glucose metabolism has been implicated as a cause for the observed cardiac dysfunction in diabetics. Dramatic increase in polyol pathway flux during hyperglycemia could cause damage to blood vessels that leads to heart failure. Recent investigations and patent applications suggest the interesting and important role of polyol pathway enzyme, aldose reductase (AR) in mediating oxidative stress-induced inflammatory signals. AR inhibitors have been shown to prevent or delay the onset of cardiovascular complications such as ischemic injury, restenosis and atherosclerosis. In this review, we have focused on describing the pivotal role of AR in the pathogenesis of cardiovascular complications and use of AR inhibitors as emerging therapeutic strategies in preventing cardiovascular complications.

AB - Diabetes is a major metabolic disorder and leading cause of morbidity and mortality in the developed world. Indeed, vascular complications are the major cause of mortality in diabetics. Impaired glucose metabolism has been implicated as a cause for the observed cardiac dysfunction in diabetics. Dramatic increase in polyol pathway flux during hyperglycemia could cause damage to blood vessels that leads to heart failure. Recent investigations and patent applications suggest the interesting and important role of polyol pathway enzyme, aldose reductase (AR) in mediating oxidative stress-induced inflammatory signals. AR inhibitors have been shown to prevent or delay the onset of cardiovascular complications such as ischemic injury, restenosis and atherosclerosis. In this review, we have focused on describing the pivotal role of AR in the pathogenesis of cardiovascular complications and use of AR inhibitors as emerging therapeutic strategies in preventing cardiovascular complications.

KW - Aldose reductase

KW - Cardiovascular & Ischemia

KW - Diabetes

KW - Inflammation

KW - Oxidative stress

KW - Polyol

UR - http://www.scopus.com/inward/record.url?scp=77950158331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950158331&partnerID=8YFLogxK

U2 - 10.2174/157489010790192683

DO - 10.2174/157489010790192683

M3 - Article

VL - 5

SP - 25

EP - 32

JO - Recent Patents on Cardiovascular Drug Discovery

JF - Recent Patents on Cardiovascular Drug Discovery

SN - 1574-8901

IS - 1

ER -